FIGURE 1.

Schematic drawing of Doxy pharmacological treatments in hemiparkinsonian mice with established LID. Eighty-five mice were selected after 6-OHDA stereotaxic surgery (solutions of 2.5 or 3.75 µg µl⁻¹ of 6-OHDA were used for Doxy 20 mg kg⁻¹ or 40 mg kg⁻¹ treatment groups, respectively) employing the apomorphine rotational test (0.5 mg.kg-1 s. c.). These mice were then treated chronically with l-DOPA for 21 days (25 mg kg⁻¹ + benserazide 10 mg kg⁻¹ i. p. once/day) and scored for AIMs. Once AIMs had been evaluated, hemiparkinsonian dyskinetic mice were divided into Veh- and Doxy (20 and 40 mg.kg⁻¹ s. c.)-treated groups with equivalent AIMs scores. Then, a sub-chronic treatment with Doxy + L-DOPA or Veh + L-DOPA was administered for the next 5 days. During this period, mice were scored for AIMs on days 1, 3, and 5.